Contact:
sales@biotechnologyforums.com to feature here

Thread Rating:
  • 0 Vote(s) - 0 Average
  • 1
  • 2
  • 3
  • 4
  • 5
Baxter International Inc. latest updates and job openings
#1
Baxter International Inc. is one of the leading names in the world of biotechnology. Baxter is the chief manufacturer of vaccines, products for regenerative medicines, recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders. It’s US based organization, with its presence all over the world. With over 48,500 employees aiming at providing advanced patient worldwide, it is well spread in North America, Europe, Middle East and Africa, Latin America/Canada and Asia Pacific. The areas this company focuses on are:

-Acute and Intensive Care Pharmaceuticals
-Anesthesia
-BioSurgery
-Clinical Nutrition
-Critical Care
-Fluid Management Systems
-Hematologic Malignancies
-Hematology/Hemophilia
-Home Care Therapies
-Immunology/Inflammation
-Infusion Systems/IV Tubing
-Oncology
-Pharmaceuticals/Solutions/Drug Delivery
-Pulmonology
-Rare/Orphan Diseases
-Regenerative Medicine
-Renal/Dialysis Drugs and Devices
-Vaccines

Here is the list of latest happenings in the organization along with the job openings available.
On July 5th, Amsterdam, Netherlands, during 24th Annual Congress of the ISTH Baxter revealed its studies featuring ADVATE. The findings from a post-hoc analysis of ADVATE reflected on the effectiveness of prophylaxis treatment by closely monitoring the levels of recombinant treatment in a patient's body.

More on ADVATE

ADVATE [Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method] a leading recombinant treatment available for patients with hemophilia A. ADVATE is approved in 58 countries worldwide, including the United States, Canada, 27 countries in the European Union, Argentina, Australia, Brazil, Chile, China, Colombia, Croatia, Hong Kong, Iceland, Iraq, Japan, Macau, Malaysia, New Zealand, Norway, Panama, Puerto Rico, Serbia, Singapore, South Korea, Suriname, Switzerland, Taiwan, Uruguay and Venezuela.

RIXUBIS, first new recombinant factor IX (rFIX) for the treatment of hemophilia B got approval by the United States Food and Drug Administration (FDA) on June 27, 2013. It is the only rFIX used for both routine prophylaxis and control of bleeding episodes in patients with hemophilia B.
  • Sessions for critical thinking and debate presented by Baxter’s employees at Chicago High School
Muchin College Prep's magazine club was launched by the company's African American Leadership Council (AALC) and six Baxter International Inc. employee volunteers to provide students a source of keeping their knowledge up-to-date on current events and hot topics in every domain.

Apply here for recent Job openings in the company.

[Image: baxter.png]

Thank you!
Ruchika
Self Employed
Like Post Reply
  


Messages In This Thread
Baxter International Inc. latest updates and job openings - by Ruchika - 07-07-2013, 06:02 PM
Possibly Related Threads…
Thread
Author
  /  
Last Post
Replies: 15
Views: 457,175
04-28-2018, 03:45 PM
Last Postkm sanju
Replies: 0
Views: 8,711
03-31-2016, 09:06 PM
Last PostHEL Group
Replies: 0
Views: 16,188
07-25-2015, 04:16 AM
Last Postgmshim
Replies: 1
Views: 17,852
10-10-2013, 04:17 PM
Last Postpriyasaravanan_1406



Users browsing this thread:
1 Guest(s)

Baxter International Inc. latest updates and job openings00